Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study

The Lancet Neurology

Volumn 10, Issue 9, 2011, Pages 797-805

  Iranzo, Alex ^a,b,c   Valldeoriola, Francesc ^a,b,c   Lomeña, Francisco ^a,b,c,d   Molinuevo, José Luis ^a,c   Serradell, Mónica ^a,b   Salamero, Manel ^a,c,d   Cot, Albert ^d,e   Ros, Domènec ^c,d,e   Pavía, Javier ^a,c,d,e   Santamaria, Joan ^a,b,c,d   Tolosa, Eduardo ^a,b,c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL) NORTROPANE I 123; DOPAMINE TRANSPORTER; IODINE 123; IOFLUPANE I 123; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; IDIOPATHIC RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER; MALE; OCCIPITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER;

AGED; COHORT STUDIES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REM SLEEP BEHAVIOR DISORDER; SUBSTANTIA NIGRA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 80051665062     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70152-1     Document Type: Article

References (57)

1. Rascol O " Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009, 72(suppl 2):S51-S58.
2. Olanow CW, Kieburtz K Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010, 25:1774-1779.
3. Tolosa E, Gaig C, Santamaría J, Compta Y Diagnosis and the premotor phase of Parkinson disease. Neurology 2009, 72(suppl 2):S12-S20.
4. McGeer PL, Itagaki S, Akiyama S, McGeer EG Rate of cell death in parkinsonism indicate active neuropathological process. Ann Neurol 1988, 24:574-576.
5. Fearnley JM, Lees AJ Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
6. Braak H, Rüb U, Gai WP, Del Tredici K Idiopathic Parkinson's disease: possible routes by which vulnerable types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003, 110:517-536.
7. Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011, 118:821-839.
8. Booji J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:133-140.
9. Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG Correlation of Parkinson's disease severity and duration with [123I]-FP-CIT SPECT striatal uptake. Mov Disord 2000, 15:692-698.
10. Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 2005, 26:421-426.
11. Ransamayr G, Seppi K, Donnemiller E Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001, 28:1523-1528.
12. Walker Z, Costa DC, Walker RWH, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. A comparison. Neurology 2004, 62:1568-1572.
13. El Fakhri G, Habert MO, Maksud P, et al. Quantitative simultaneous (99m) Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2006, 33:87-92.
14. Muñoz E, Iranzo A, Rauek S, et al. Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). J Neurol 2011, published online June 3. 10.1007/s00415-011-6108-8.
15. Marek K, Innis R, van Dyck C, et al. [123I]β-CIT SPECT imaging assessment on the rate of Parkinson's disease. Neurology 2001, 57:2089-2094.
16. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J Striatal dopamine transporter binding in early to moderate advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001, 22:721-725.
17. Winogrodzka A, Bergmans P, Booji J, van Royen EA, Stoof JC, Wolters EC [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003, 74:294-298.
18. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brücke T Measuring the rate of progression of Parkinson's disease over a 5-year period with β-CIT SPECT. Mov Disord 2003, 18:1266-1272.
19. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005, 32:1176-1185.
20. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661. for the Parkinson study group.
21. Iranzo A, Santamaria L, Tolosa E The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med Rev 2009, 13:385-401.
22. Boeve B REM sleep behavior disorder. Ann NY Acad Sci 2010, 1184:15-54.
23. Schenck CH, Bundlie SR, Mahowald MW Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996, 46:388-392.
24. Schenck CH, Bundlie SR, Mahowald MW REM sleep behaviour disorder (RBD) delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the maximum and minimum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003, 26(suppl):A316.
25. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disease: a descriptive study. Lancet Neurol 2006, 5:572-577.
26. Iranzo A, Molinuevo JL, Santamaria J, et al. Sixty-four percent of patients with idiopathic REM sleep behavior disorder developed a neurological disorder after a mean clinical follow-up of seven years. Sleep 2008, 31(suppl):A280.
27. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
28. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499.
29. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55:1410-1412.
30. Eisensehr I, Linke R, Noachtar S, Schwarz J, Guildehaus FJ, Tatsch K Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. Brain 2000, 123:1155-1160.
31. Stiasny-Kolster K, Doerr Y, Möller, et al. Combination of " idiopathic" REM sleep behavior disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
32. Iranzo A, Lomeña F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010, 9:1070-1077. for the Sleep Innsbruck Barcelona (SINBAR) group.
33. Fahn S, Elton RL Unified Parkinson's Disease Rate Scale. Recent developments in Parkinson's disease 1987, 153-163. members of the UPDRS Development Committee, Macmillan Health Care Information, Florharm Park, NJ. 1st edn. S. Fahn, C.D. Marsden, D.B. Calne, M. Golgstein (Eds.).
34. Hughes AJ, Daniel SE, Kilford L, Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
35. Tabachnick BG, Fidell LS Using multivariate statistics 2007, Pearson, Boston. 5th edn.
36. Bernheimer H, Birkmayer W, Hornykiewitz O, Jellinger K, Seitelberger F Brain dopamine damage and the syndromes of Parkinson and Huntington. J Neurol Sci 1973, 20:415-455.
37. Kish SJ, Shannak K, Hornykiewcz O Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988, 14:876-880.
38. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ Measuring the rate of progression and estimating the preclinical period of Parkinson disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998, 64:314-319.
39. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001, 16:608-615.
40. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson's disease as determined by serial positron emission tomographic imaging of serial fluorodopa F18 activity. Arch Neurol 2005, 62:378-382.
41. de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011, 69:803-810.
42. Miyamoto T, Orimo S, Miyamoto M, et al. Follow-up PET studies in case of idiopathic REM sleep behaviour disorder. Sleep Med 2010, 11:100-101.
43. Iranzo A, Ratti PL, Casanova-Molla, Serradell M, Vilaseca I, Santamaria J Excessive muscle activity increases over time in idiopathic REM sleep behavior disorder. Sleep 2009, 32:1149-1153.
44. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir J Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011, 69:811-818.
45. Fantini ML, Farini E, Ortelli P, et al. Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. Sleep 2011, 34:619-625.
46. Stockner H, Iranzo A, Seppi K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009, 24:1906-1909.
47. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130:1834-1846.
48. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
49. Brück A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO A follow-up study on 6-[18F]Fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009, 24:1009-1015.
50. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003, 54:93-101.
51. Morrish P, Swale G, Brooks D Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995, 59:597-600.
52. Marek K, Seibyl J, Scanley B, et al. [I-123] CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996, 46:231-237.
53. Tang CC, Poston KL, Dhawan V, Eidelberg D Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010, 30:1049-1056.
54. Troiano AR, Schulzer M, de la Fuente-Fernandez, et al. Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 2010, 64:146-151.
55. Larsson M, Farde L, Hummel T, Erixon Lindroth N, Bäckman L Age-related loss of olfactory sensitivity: association to dopamine transporter binding in putamen. Neuroscience 2009, 161:422-426.
56. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995, 36:1175-1181.
57. Iranzo A, Santamaria J Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep 2005, 28:203-206.